Wockhardt Past Earnings Performance
Past criteria checks 0/6
Wockhardt's earnings have been declining at an average annual rate of -26.2%, while the Pharmaceuticals industry saw earnings growing at 15.2% annually. Revenues have been declining at an average rate of 4.3% per year.
Key information
-26.2%
Earnings growth rate
-19.5%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | -4.3% |
Return on equity | -9.6% |
Net Margin | -11.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You
Aug 20Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jul 27Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Jun 30Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation
Jun 22Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%
Feb 21There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump
Dec 19There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues
Oct 14Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Feb 18Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being
Jul 26Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
May 18Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Jan 26What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?
Dec 01Revenue & Expenses Breakdown
How Wockhardt makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 29,250 | -3,430 | 6,358 | 0 |
31 Mar 24 | 28,300 | -4,630 | 6,298 | 0 |
31 Dec 23 | 27,760 | -5,010 | 6,170 | 0 |
30 Sep 23 | 27,740 | -5,140 | 6,150 | 0 |
30 Jun 23 | 27,000 | -6,260 | 6,120 | 0 |
31 Mar 23 | 26,570 | -5,590 | 6,380 | 0 |
31 Dec 22 | 26,280 | -6,100 | 7,050 | 0 |
30 Sep 22 | 27,820 | -5,210 | 7,530 | 0 |
30 Jun 22 | 29,650 | -2,980 | 7,680 | 0 |
31 Mar 22 | 32,300 | -2,440 | 7,509 | 0 |
31 Dec 21 | 32,074 | -787 | 7,596 | 0 |
30 Sep 21 | 31,175 | -567 | 7,637 | 0 |
30 Jun 21 | 29,696 | -867 | 7,829 | 0 |
31 Mar 21 | 27,080 | -2,990 | 7,930 | 0 |
31 Dec 20 | 27,633 | -1,780 | 8,041 | 0 |
30 Sep 20 | 24,910 | -2,583 | 7,154 | 0 |
30 Jun 20 | 27,167 | -3,181 | 7,700 | 0 |
31 Mar 20 | 28,440 | -1,638 | 7,704 | 0 |
31 Dec 19 | 35,136 | -1,320 | 9,513 | 0 |
30 Sep 19 | 36,903 | -2,127 | 9,884 | 0 |
30 Jun 19 | 40,138 | -1,533 | 10,275 | 0 |
31 Mar 19 | 35,658 | -2,897 | 8,943 | 0 |
31 Dec 18 | 41,851 | -3,346 | 10,574 | 0 |
30 Sep 18 | 41,445 | -3,043 | 10,409 | 0 |
30 Jun 18 | 40,536 | -2,848 | 9,424 | 0 |
31 Mar 18 | 39,245 | -6,083 | 10,293 | 0 |
31 Dec 17 | 37,822 | -6,285 | 10,261 | 0 |
30 Sep 17 | 37,724 | -6,416 | 10,444 | 0 |
30 Jun 17 | 38,148 | -6,213 | 9,537 | 0 |
31 Mar 17 | 39,664 | -1,957 | 10,542 | 0 |
31 Dec 16 | 41,695 | 485 | 10,395 | 0 |
30 Sep 16 | 42,485 | 1,745 | 10,392 | 0 |
30 Jun 16 | 44,134 | 2,499 | 10,446 | 0 |
31 Mar 16 | 44,532 | 2,507 | 10,387 | 0 |
31 Dec 15 | 46,085 | 3,168 | 15,201 | 194 |
30 Sep 15 | 49,148 | 6,031 | 14,960 | 194 |
30 Jun 15 | 45,497 | 4,992 | 8,914 | 0 |
31 Mar 15 | 44,815 | 4,049 | 9,442 | 0 |
31 Dec 14 | 43,867 | 4,452 | 13,521 | 181 |
30 Sep 14 | 42,410 | 4,024 | 13,332 | 181 |
30 Jun 14 | 44,632 | 5,374 | 7,976 | 0 |
31 Mar 14 | 48,304 | 8,407 | 13,899 | 181 |
31 Dec 13 | 52,772 | 11,010 | 12,610 | 0 |
30 Sep 13 | 54,759 | 12,244 | 12,367 | 0 |
Quality Earnings: WOCKPHARMA is currently unprofitable.
Growing Profit Margin: WOCKPHARMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: WOCKPHARMA is unprofitable, and losses have increased over the past 5 years at a rate of 26.2% per year.
Accelerating Growth: Unable to compare WOCKPHARMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WOCKPHARMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.3%).
Return on Equity
High ROE: WOCKPHARMA has a negative Return on Equity (-9.61%), as it is currently unprofitable.